




Monkeypox (MPX) Community Update

September 28, 2022 AIDS Action Baltimore

Maryland Department of Health



Speakers



Peter DeMartino, PhD Director Infectious Disease Prevention and Health Services Bureau

cell: 443.717.0740 e: <u>peter.demartino@maryland.gov</u>



PHPA: Mission and Vision

MISSION

The mission of the Prevention and Health Promotion Administration is to protect, promote and improve the health and well-being of all Marylanders and their families through provision of public health **leadership** and through community-based public health efforts in **partnership** with local health departments, providers, community based organizations, and public and private sector agencies, giving special attention to at-risk and **vulnerable populations**.

VISION

The Prevention and Health Promotion Administration envisions a future in which all Marylanders and their families enjoy optimal health and well-being.



On-Going Community Engagement

GROUP	STAFF	CONTACT
• Statewide HIV Planning Group (HPG)	Carmi Washington Flood	Carmi.Washington-Flood@maryland.gov
 Statewide Faith Based Advisory Board (SFAB) 		
• <u>Standing Advisory Committee on</u> <u>Opioid-Associated Disease Prevention</u> <u>and Outreach Programs</u> (SAC)	Erin Russell	mdh.syringeservices@maryland.gov
• Transgender Response Team (TRT)	Jean-Michel Brevelle	Jean-Michel.Brevelle@maryland.gov





Monkeypox (MPX)

Comprehensive Outbreak Response



MPX: MDH Outbreak Response Plan

Four pillars (built on federal plan, June 28, 2022)

- Testing
 - Expanded commercial laboratory testing
- Case Identification and Contact Tracing
 - Make recommendations for PEP and treatment, as appropriate
- Vaccine
 - Limited resource focused on <u>outbreak</u> response
- Provider and Community Engagement
 - Messaging around prevention, identification, and testing
 - Harm reduction strategies



Moving Forward

- 1) Case Updates
- 2) Provider and Community Engagement; Resources Available
- 3) Vaccine



7



Monkeypox (MPX) 2022 Outbreak Case Updates



MPX Data

2022 Outbreak Cases and Data Data as of September 26 2022

U.S. Cases: 25,162

Global Cases: 65,933

Total Vaccines Administered:

684,980

Maryland Outbreak Cases

Total Positive Cases: 650

Total Vaccine Doses Administered: 7,873



Marylanders Currently Impacted

- Cis and Transgender Gay, Bisexual, and other Men who Have Sex with Men (GBMSM)
- Transgender women or nonbinary persons assigned male at birth who have sex with men
- *Most frequently reported transmissions:*
 - multiple or unknown sexual partners
 - sex-on-premises venues or events
 - geospatial dating applications
 - sex work





Provider and Community Engagement

MPX-forward/STI-informed



MPX Engagement: Provider Outreach

Comprehensive Response:

- Ensuring linkage to needed services despite vaccine constraints
- Leveraging existing sexual health and affliated providers including
 - Field Services, Disease Intervention Specialists, HIV PrEP Navigators, HIV providers
 - Navigation to health resources including vaccine
 - Potential for STI and MPX coinfection
- Identifying opportunities for provider awareness
 - Symptoms
 - Testing
 - Harm Reduction Strategies



MPX Engagement: Community Outreach

Collaborative Strategy:


- Ensuring access to information

- Updating resources as new information emerges
 - Web pages, factsheets, guidance docs, social media
- Deploying state and local dissemination networks and engaging diverse community partners and tactics
 - Local Health Departments, Office of Minority Health and Health Disparities, HIV & STI programs
 - Targeted messaging, language translations
- Elevating awareness in higher-risk communities
 - Regionalizing messaging and media responses
 - Presenting data, exchanging information with partners
 - Presentation forums, listening sessions



MDH Website

health.maryland.gov/monkeypox



Coming in October

The STD/HIV Prevention Training Center at Johns Hopkins, in partnership with Baltimore City Health Department and the Maryland Department of Health, is pleased to bring you a free webinar series designed to increase your capacity to diagnose, treat, and prevent Monkeypox in your clinical setting.









October 12, 2022	Registration Link:
Time: 9:00-10:00am ET	https://courses.nnptc.org/class_info
Topic: Clinical Overview of Monkeypox	rmation.html?id=3465
Matthew Hamill, MBCHB, PhD, MPH	
October 14, 2022	Registration Link:
Time: 1:00-2:00pm ET	https://courses.nnptc.org/class_info
Topic: My Patient has Monkeypox, Now What? Treatment	rmation.html?id=3467
and Clinical Management Options	
Kelly Gebo, MD, MPH	
October 14, 2022	Registration Link:
Time: 3:00-4:00pm ET	https://courses.nnptc.org/class_info
Topic: Nuts and Bolts of Testing for Monkeypox	rmation.html?id=3466
Elizabeth Gilliams, MD	
October 17, 2022	Registration Link:
Time: 3:00-4:30pm ET	https://courses.nnptc.org/class_info
Topic: Monkeypox Vaccines	rmation.html?id=3468
Noreen Hynes, MD, MPH and Peter DeMartino, PhD	Marvland

DEPARTMENT OF HEALTH



Transmission Interruption Vaccine



MPX: Vaccine Availability

- <u>JYNNEOS</u>: live, non-replicating vaccinia vaccine (2 doses, 28 days apart)
- <u>ACAM2000</u>: live, replicating vaccinia vaccine (1 dose)
 - Not for immunocompromised, pregnant individuals, or those with certain skin conditions
 - Not a part of Maryland's current outbreak response
- JYNNEOS is available at all local health departments (LHD), Chase Brexton, Kaiser Permanente Infectious Disease sites, and other providers receiving vaccine from LHDs



MDH Vaccine Eligibility: PEP

MPX vaccine should be administered for PEP to:	Public Health Identified Individuals : Known close contacts who are identified by public health via case investigation, contact tracing, and risk exposure assessments
	Those with Occupational Exposure : Healthcare workers who may have been exposed to a known case without proper precautions (Personal Protective Equipment)



Vaccine Eligibility: ePEP

MPX vaccine should be administered for **ePEP** to: **Self-Identified Partners of Cases:** People who are aware that one of their sexual partners from the past 2 weeks has been diagnosed with MPX

Currently Impacted Community Members: People who have had multiple sexual partners in the past 2 weeks



Vaccine Eligibility: PrEP

- This approach refers to administering a vaccine to someone at high risk for MPX (for example, laboratory workers who handle specimens that might contain MPX virus).
- Effective the week of September 19, 2022, populations eligible for PrEP include individuals with presumed or potential sexually associated exposure, in particular those individuals with immunocompromising conditions and members of communities at higher risk including gay, bisexual, and other men who have sex with men (GBMSM).



Vaccine Eligibility: PrEP

Effective week of September 19, 2022, MPX vaccine should be administered for **PrEP to:** **Those with Potential Sexually Associated**

Exposure: People with multiple or unknown sexual partners, with priority being given to immunocompromised individuals and members of impacted communities including GBMSM





To pre-register for the MPX vaccine, visit:

health.maryland.gov/monkeypox



1:55 7 Maryland.gov J m Human Monkeypox

Overview

The Maryland Department of Health (MDH) is working with partners to monitor the global human monkeypox outbreak and provide information to residents. Check this page for updates and follow us at http://www.twitter.com/MDHealthDept and

https://www.facebook.com/MDHealthC pt.

Click here to move ahead to our human monkeypox resources section

NEW Click here to sign up for Maryland's MPX vaccine preregistration. The Maryland Statewide MPX Vaccine Pre-Registration System



Goals of the Pre-Registration System

- Provide Marylanders seeking vaccine an opportunity to self-identify
- Provide LHDs a tool to populate MPX ePEP vaccination clinics
- Inform vaccination strategies
- Support responsive vaccine initiatives

Not meant to replace community engagement or be the only means to identify Marylanders seeking vaccine

Distribution to Local Providers

All LHDs are encouraged to partner with local partners:

- Share vaccine with clinical partners including primary care, infectious disease, sexual and reproductive health, and HIV providers
- Collaborate with community organizations including Faith-Based Community Organizations, PFLAG chapters, and Pride and other LGBTIQA+ organizations
- Check with your local FQHC/CHC
- Partner with College/University Health Services and LGBTIQA+ student organizations

MDH will begin to expand vaccine distribution directly to healthcare access points (Kaiser pilot program)



CDC opening applications for Monkeypox Vaccine Equity Pilot Program

• New CDC Vaccine Equity Pilot Program

- 10,000 vials of vaccine (enough for up to 50,000 intradermal doses) have been set aside for this national pilot program.
- For each project selected, submitting jurisdictions can request an advance of vaccines based on planned events and approaches. Initially, CDC recommends requesting up to 100 vials (300–500 doses) upfront per project; this may be reevaluated once the project begins.

CDC: <u>https://www.cdc.gov/poxvirus/monkeypox/health-departments/vaccine-equity-pilot.html</u> MDH Application: <u>https://forms.gle/zt6mLDNDs61apA3S6</u>

Source: <u>https://www.cdc.gov/poxvirus/monkeypox/health-departments/vaccine-equity-pilot.html</u> Accessed 9/19/22

Questions? Thank you!





Prevention and Health Promotion Administration